3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
enfortumab vedotin
4
pembrolizumab
3
vinflunine
2
Ramucirumab
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
rucaparib
1
Standard of Care
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
1
Molecular Diagnostic Techniques
1
LHRH, lysine(6)-doxorubicin
1
Immunotherapy
1
Icrucumab
1
IMC-18F1
1
Drug Therapy
1
Carboplatin
1
Biological Therapy
1
ALT-801
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ureteral Neoplasms
×
Immunotherapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled